219 related articles for article (PubMed ID: 35981465)
21. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
Liu S; Deng B; Yin Z; Lin Y; An L; Liu D; Pan J; Yu X; Chen B; Wu T; Chang AH; Tong C
Am J Hematol; 2021 Jun; 96(6):671-679. PubMed ID: 33725422
[TBL] [Abstract][Full Text] [Related]
22. CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies.
Bueno C; Barrera S; Bataller A; Ortiz-Maldonado V; Elliot N; O'Byrne S; Wang G; Rovira M; Gutierrez-Agüera F; Trincado JL; González-González M; Morgades M; Sorigué M; Bárcena P; Zanetti SR; Torrebadell M; Vega-Garcia N; Rives S; Mallo M; Sole F; Mead AJ; Roberts I; Thongjuea S; Psaila B; Juan M; Delgado J; Urbano-Ispizúa A; Ribera JM; Orfao A; Roy A; Menendez P
Blood; 2022 Jul; 140(1):38-44. PubMed ID: 35421218
[TBL] [Abstract][Full Text] [Related]
23. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.
Löffler A; Kufer P; Lutterbüse R; Zettl F; Daniel PT; Schwenkenbecher JM; Riethmüller G; Dörken B; Bargou RC
Blood; 2000 Mar; 95(6):2098-103. PubMed ID: 10706880
[TBL] [Abstract][Full Text] [Related]
24. TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL.
Malik-Chaudhry HK; Prabhakar K; Ugamraj HS; Boudreau AA; Buelow B; Dang K; Davison LM; Harris KE; Jorgensen B; Ogana H; Pham D; Schellenberger U; Van Schooten W; Buelow R; Iyer S; Trinklein ND; Rangaswamy US
MAbs; 2021; 13(1):1890411. PubMed ID: 33818299
[TBL] [Abstract][Full Text] [Related]
25. Efficient chimeric antigen receptor targeting of a central epitope of CD22.
Casey NP; Klee CH; Fåne A; Caulier B; Graczyk-Jarzynka A; Krawczyk M; Fidyt K; Josefsson SE; Köksal H; Dillard P; Patkowska E; Firczuk M; Smeland EB; Winiarska M; Myklebust JH; Inderberg EM; Wälchli S
J Biol Chem; 2023 Jul; 299(7):104883. PubMed ID: 37269947
[TBL] [Abstract][Full Text] [Related]
26. Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia.
Locatelli F; Eckert C; Hrusak O; Buldini B; Sartor M; Zugmaier G; Zeng Y; Pilankar D; Morris J; von Stackelberg A
Pediatr Blood Cancer; 2022 Aug; 69(8):e29715. PubMed ID: 35482538
[TBL] [Abstract][Full Text] [Related]
27. Blinatumomab for the treatment of B-cell lymphoma.
Oak E; Bartlett NL
Expert Opin Investig Drugs; 2015 May; 24(5):715-24. PubMed ID: 25739952
[TBL] [Abstract][Full Text] [Related]
28. CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study.
Wei G; Zhang Y; Zhao H; Wang Y; Liu Y; Liang B; Wang X; Xu H; Cui J; Wu W; Zhao K; Nagler A; Chang AH; Hu Y; Huang H
Cancer Immunol Res; 2021 Sep; 9(9):1061-1070. PubMed ID: 34290048
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
Ribera JM
Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
[TBL] [Abstract][Full Text] [Related]
30. Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking.
Braig F; Brandt A; Goebeler M; Tony HP; Kurze AK; Nollau P; Bumm T; Böttcher S; Bargou RC; Binder M
Blood; 2017 Jan; 129(1):100-104. PubMed ID: 27784674
[TBL] [Abstract][Full Text] [Related]
31. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.
Mølhøj M; Crommer S; Brischwein K; Rau D; Sriskandarajah M; Hoffmann P; Kufer P; Hofmeister R; Baeuerle PA
Mol Immunol; 2007 Mar; 44(8):1935-43. PubMed ID: 17083975
[TBL] [Abstract][Full Text] [Related]
32. [Production, identification and redirected cytotoxicity of CD3/CD19 bispecific monoclonal antibody].
Chen X; Shen D; Sun T; Bai J; Huang L
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Oct; 20(5):351-6. PubMed ID: 11717991
[TBL] [Abstract][Full Text] [Related]
33. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts.
Feucht J; Kayser S; Gorodezki D; Hamieh M; Döring M; Blaeschke F; Schlegel P; Bösmüller H; Quintanilla-Fend L; Ebinger M; Lang P; Handgretinger R; Feuchtinger T
Oncotarget; 2016 Nov; 7(47):76902-76919. PubMed ID: 27708227
[TBL] [Abstract][Full Text] [Related]
34. Development and functional characterization of novel fully human anti-CD19 chimeric antigen receptors for T-cell therapy.
Dai Z; Hu X; Jia X; Liu J; Yang Y; Niu P; Hu G; Tan T; Zhou J
J Cell Physiol; 2021 Aug; 236(8):5832-5847. PubMed ID: 33432627
[TBL] [Abstract][Full Text] [Related]
35. Killing of autologous B-lineage malignancy using CD3 x CD19 bispecific monoclonal antibody in end stage leukemia and lymphoma.
Haagen IA; Geerars AJ; de Lau WB; Clark MR; van de Griend RJ; Bast BJ; de Gast BC
Blood; 1994 Jul; 84(2):556-63. PubMed ID: 7517719
[TBL] [Abstract][Full Text] [Related]
36. Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab.
Köhnke T; Krupka C; Tischer J; Knösel T; Subklewe M
J Hematol Oncol; 2015 Oct; 8():111. PubMed ID: 26449653
[TBL] [Abstract][Full Text] [Related]
37. Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review.
Du J; Zhang Y
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1575-1582. PubMed ID: 32222815
[TBL] [Abstract][Full Text] [Related]
38. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.
Tapia-Galisteo A; Álvarez-Vallina L; Sanz L
J Hematol Oncol; 2023 Jul; 16(1):83. PubMed ID: 37501154
[TBL] [Abstract][Full Text] [Related]
39. Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL.
Zhao Y; Aldoss I; Qu C; Crawford JC; Gu Z; Allen EK; Zamora AE; Alexander TB; Wang J; Goto H; Imamura T; Akahane K; Marcucci G; Stein AS; Bhatia R; Thomas PG; Forman SJ; Mullighan CG; Roberts KG
Blood; 2021 Jan; 137(4):471-484. PubMed ID: 32881995
[TBL] [Abstract][Full Text] [Related]
40. Release of cytokines and soluble cell surface molecules by PBMC after activation with the bispecific antibody CD3 x CD19.
Klein SC; Boer LH; de Weger RA; de Gast GC; Bast EJ
Scand J Immunol; 1997 Nov; 46(5):452-8. PubMed ID: 9393627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]